Abstract:ID 93978 Poster Board 520 Altered dopamine signaling in the central nervous system (CNS) has been the subject of many studies, as it has become a fundamental feature of numerous CNS diseases and disorders, including Parkinson's disease (PD) and substance use disorder (SUD). The dopamine transporter (DAT) is the primary regulator of dopamine (DA) signaling in the central nervous system (CNS) and in the periphery. This member of the re-uptake-1 monoamine transporters (MATs) clears extracellular dopamine by transporting it into the cell for storage. Recent studies have shown that peripheral immune cells such as monocytes and macrophages express DAT and the norepinephrine transporter (NET), and that DAT regulates innate immune response. Alterations of DAT in the CNS impacts the expression of this protein in peripheral immune cells affecting immune regulation. Development of methodologies and tools that will facilitate our understanding of the mechanism underlying these observations can facilitate strategies to study DAT-associated disease and disorders in the periphery. Fluorescently labelled ligands (FLL) have proven useful as tools to study protein expression, localization, and distribution and downstream processes in distinct live cell systems, opening a venue to study endogenously expressed proteins. In this work, we set out to develop a high affinity and selective FLL for the detection of DAT in peripheral blood mononuclear cells (PBMCs) by flow cytometry. For our synthetic design, we identified two atypical DAT inhibitors, JJC8-087 and JJC8-089, as parent ligands. These compounds bind with high affinity to DAT and selectivity over SERT and NET. Fluorescent labelling of the parent ligand was based on previously reported structure-activity relationship studies. Binding affinities of all final compounds for rDAT, rSERT and rNET were obtained via radioligand binding assay in Sprague-Dawley rat brain tissue and hDAT-HEK293 cell membranes. PBMCs were isolated from whole blood via density media centrifugation and samples treated with either the FLL or a control antibody were analyzed via flow cytometry on a 5-laser Cytek Aurora Spectral Cytometer. Probes based on JJC8-087 demonstrated the highest DAT affinity and were selective with respect to SERT and NET. The lead DiSulfoCy5 FLL, GC04-38 (rDAT K i = 159 nM) was ~26-fold rDAT selective over rSERT ( K i = 4.2 mM) and >63-fold selective over rNET ( K i = >10 mM), in addition, a similar binding affinity for hDAT was obtained ( K i = 191 nM). GC04-38 was used to label DAT in both mouse and human peripheral blood mononuclear cells (PBMCs) and analyzed via flow cytometry revealing comparable results with a control DAT antibody, reducing the time of sample preparation from 165 minutes (antibody control) to 30 min (FLL). We validated the selective detection of DAT with PBMCs isolated from a DAT knockout mouse demonstrating high specificity of this FLL. Overall, our results suggest a robust use for this novel FLL probe to increase our understanding of CNS-peripheral DAT regulation mechanisms underlying health and disease. This research is funded by the National Institutes of Health (NIH) – National Institute on Drug Abuse (NIDA) - Intramural Research Program.

Characterization of the neuronal dopamine transporter DAT in human blood platelets

Molecular Imaging of Striatal Dopamine Transporters in Major Depression—a Meta-Analysis

Dopamine transporter silencing in the rat: systems-level alterations in striato-cerebellar and prefrontal-midbrain circuits

Reduced Striatal Dopamine Transporters in People with Internet Addiction Disorder

Dopamine Transporter Trafficking: Rapid Response on Demand.

Fluorescently Labelled Ligand Allow Detection of DAT in Human and Mouse Peripheral Blood Monocytes by Flow Cytometry

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue

Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities

Dopamine transporter endocytic trafficking: Neuronal mechanisms and potential impact on DA‐dependent behaviors

Study on Function and Density of Dopamine Transporter in Peripheral Lymphocyte of Patients with Parkinson's Disease

DAT and TH expression marks human Parkinson’s disease in peripheral immune cells

Electrophysiological and Behavioral Markers of Hyperdopaminergia in DAT-KO Rats

Expression and regulation of the human dopamine transporter in a neuronal cell line (vol 59, pg 66, 1998)

The Lack of Dopamine Transporter Is Associated With Conditional Associative Learning Impairments and Striatal Proteomic Changes

Disruption of the PDZ domain-binding motif of the dopamine transporter uniquely alters nanoscale distribution, dopamine homeostasis, and reward motivation

Further studies on platelet serotonin transporter binding in depression

Changes of dopamine transporters in major depression and Parkinson disease

Characterization of Novel Pyrovalerone Analogs as Potential Dopamine Transporter Irreversible Ligands

Lack of Cdk5 activity is involved on Dopamine Transporter expression and function: Evidences from an animal model of Attention-Deficit Hyperactivity Disorder

Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse